This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Vir Biotechnology's Tobevibart monotherapy and combination therapy with Elebsiran in patients with Hepatitis Delta Virus
Ticker(s): VIRWho's the expert?
Institution: Federal University of Acre – School of Medicine Acre State Hospital Foundation
- Federal University of Acre – School of Medicine Acre State Hospital Foundation Infectious Diseases and Tropical Hepatology Unit
- Manages 50 pts with Hep D
- Serves as the director of the Brazilian Society of Hepatology's Viral Hepatitis Committee
Interview GoalTo study the potential of tobevibart and tobevibart + elebsiran , being developed by Vir Biotechnology for the treatment of Hepatitis Delta
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
